By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
Would this not support the effect that Mtx has a middle position?
It worked for the ACPA - high risk, while not for low risk which might not progress or really needs RX, while it leave the space for the ACPA+ to be treated by targeted biologic agent as we all are so used to.